Experienced in Peripheral T-Cell Lymphoma

Dongmei M. Ji

Shanghai, CN 
Experienced in Peripheral T-Cell Lymphoma
Shanghai, CN 
OverviewLocationsClinical Research

Overview

Dongmei Ji practices in Shanghai, China. Ji is rated as an Experienced expert by MediFind in the treatment of Peripheral T-Cell Lymphoma. Their top areas of expertise are Agranulocytosis, Peripheral T-Cell Lymphoma, Febrile Neutropenia, B-Cell Lymphoma, and Laryngectomy.

Their clinical research consists of co-authoring 49 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Peripheral T-Cell Lymphoma.

Locations

Shanghai, 200032, China
Other Locations
No.270 Dong'an Road, Xuhui, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of hLAG-3 Fusion Protein, EOC202 (Eftilagimod Alpha) Combined With Paclitaxel in Chinese Patients With Metastatic Breast Cancer
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of hLAG-3 Fusion Protein, EOC202 (Eftilagimod Alpha) Combined With Paclitaxel in Chinese Patients With Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: March 31, 2022
Intervention Type: Biological, Drug
Study Drugs: EOC202, Paclitaxel
Study Phase: Phase 1

49 Total Publications

Efbemalenograstim Alfa, an Fc Fusion Protein, Long‑Acting Granulocyte Colony-Stimulating Factor for Reducing the Risk of Chemotherapy-Induced Neutropenia: Results of a Phase II Randomized, Multicenter, Open‑Label Trial.
Efbemalenograstim Alfa, an Fc Fusion Protein, Long‑Acting Granulocyte Colony-Stimulating Factor for Reducing the Risk of Chemotherapy-Induced Neutropenia: Results of a Phase II Randomized, Multicenter, Open‑Label Trial.
Journal: Clinical drug investigation
Published: December 24, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ji's expertise for a condition
ConditionClose
      View All 18 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile